ArticleOncoTargets and therapy2020

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.

Shaowei Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.